Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01254409 · ClinicalTrials.gov registry record · Phase 1
A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
A Phase 1 study, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT01254409 is a Phase 1 study that has completed, run by Hoffmann-La Roche. The registered enrollment target is 21 participants.
The verdict
NCT01254409, a Phase 1 study, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
The aims of the study are to assess safety, tolerability, the pharmacokinetic profile, and the pharmacodynamic profile of multiple doses of PRM-151 administered IV to IPF patients.
Interventions
- OTHER Placebo
- BIOLOGICAL PRM-151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2011-03-29 |
| Est. Completion | 2012-07-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01254409
The ClinicalTrials.gov registry entry for NCT01254409 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01254409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01254409 about?
NCT01254409 is a clinical study titled "A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)". The aims of the study are to assess safety, tolerability, the pharmacokinetic profile, and the pharmacodynamic profile of multiple doses of PRM-151 administered IV to IPF patients.
What is the current status of trial NCT01254409?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2011-03-29. Estimated completion is 2012-07-02.
What interventions are being tested in trial NCT01254409?
The interventions under investigation include: Placebo (OTHER), PRM-151 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01254409?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.